Ocera Therapeutics Inc. (NASDAQ:OCRX) shares were up 2.5% during mid-day trading on Wednesday . The company traded as high as $2.50 and last traded at $2.50, with a volume of 191,033 shares changing hands. The stock had previously closed at $2.44.

Separately, Zacks Investment Research downgraded shares of Ocera Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 10th.

The stock’s 50 day moving average is $2.55 and its 200 day moving average is $2.72. The firm’s market capitalization is $54.41 million.

Ocera Therapeutics (NASDAQ:OCRX) last announced its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.02. Equities analysts expect that Ocera Therapeutics Inc. will post ($1.34) earnings per share for the current year.

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.